Mary C Wolff1, J David Leander
1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA. wolff_mary_c@lilly.com
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Selective serotonin reuptake inhibitors (SSRIs) show promise in reducing impulsive behavior by increasing delayed gratification. Combining SSRIs with a 5-HT(1A) agonist may accelerate these therapeutic effects.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: